Scenario valuation
Scenario valuation of the shares in AUXESIS PHARMA HOLDING AB (publ) prior to the launch of the company’s analgesic product ASA.P® is now available. One-Pager
May 13, 2022
No Comments
Scenario valuation of the shares in AUXESIS PHARMA HOLDING AB (publ) prior to the launch of the company’s analgesic product ASA.P® is now available. One-Pager
The shareholders in 559195-6486 AUXESIS PHARMA HOLDING AB (publ), is hereby convened to the Annual General Meeting on June 10, 2022 at 15.00 in the conference
Welcome as Board Members – Charlotta Larsson and Rune Nordström. Thank you to all shareholders for a great meeting and big thanks to Lars Larsson
Auxesis Pharma Holding AB has signed a license agreement with Pharma America Corp. in Florida, for a powerful introduction to the entire Americas. The ASA.P®
En beviljad SME status från EMA betyder att bolaget får lättare tillgång till regulatorisk, finansiell och administrativ assistans från EMA inom utveckling av företagets produkter
+46 (0)8-771 43 00
Copyright All rights reserved AUXESIS PHARMA HOLDING AB (publ) 2023